Category Uncategorized

Clinical trials are testing drugs that directly target tau protein and block its spread through the brain, offering hope for people with Alzheimer's and other dementias.

Tau PET scans are concentrated at academic medical centers, but access, insurance coverage, and regional availability remain significant barriers for most patients.

In head-to-head comparisons, p-tau217 achieved an area under the curve (AUC) of 0.96 for detecting brain pathology, compared to p-tau181's 0.76—a...

A Fremont therapy center failed to hire safely or supervise adequately, leaving a toddler vulnerable to abuse by a staff member posting explicit content online.

When a promotion becomes perceived as disrespectful or poorly timed—particularly one that openly targets a rival team—it can create negative momentum both...

Understanding FDA approval stages helps patients evaluate treatment options and recognize delays that may affect their access to new therapies.

Unvalidated cognitive tests can lead to years of unnecessary anxiety or dangerous delays in detecting real decline—making rigorous testing standards essential before any screening tool is used widely.

Blood tests for Alzheimer's are commercially available now, but most doctors haven't been trained to use them responsibly.

Redesigning websites can confuse people with cognitive challenges; familiar layouts let them accomplish tasks without relearning everything.

Breaking down complex tasks into ordered steps can dramatically cut frustration and confusion in dementia care.